Use of combined androgen blockade for advanced prostate cancer in British Columbia

Abstract

Objectives. Initial androgen deprivation therapy (ADT) for metastatic prostate cancer with combined androgen blockade (luteinizing-hormone releasing hormone agonist [LHRH agonist] plus antiandrogen) is not recommended in British Columbia (BC). However, this is difficult to monitor since ADT includes concurrent antiandrogen for the first month of LHRH agonist to prevent disease flare. We describe the prevalence of CAB use in BC and its financial impact.

Methods. This was a population-based, retrospective analysis. Patients started on LHRH agonist in January 2005 to December 2006 were identified from the BC Cancer Agency database. CAB was defined as greater than 1 month of antiandrogen concurrently with LHRH agonist. Incremental cost of CAB was based on an average 18 months of therapy from the pivotal CAB study. Incremental cost-effectiveness ratio (ICER) was based on life-year gained (LYG) from the Prostate Cancer Trialists’ Collaborative Group meta-analysis. Estimated financial impact for 2007—2008 was based on an annual increase by 5.5% in prevalence of prostate cancer in BC.

Results. A total of 2751 patients were identified. CAB was used in 607 patients (22%), associated with an incremental cost of CDN$1768 and ICER of CDN$11,220/LYG per patient. Total incremental cost was CDN$1,073,176 and estimated to be CDN$1,398,644 for January 2007 to December 2008.

Conclusion. Nearly one-quarter of patients were treated with CAB for metastatic prostate cancer even though it was not recommended in BC. Additional cost of CAB use was considerable, at CDN$1768 per patient. With increased prevalence of prostate cancer, this has important budget implication for funding agencies which do to recommend CAB. J Oncol Pharm Practice (2010) 16: 121—126.

Keywords

prostate cancer pharmacoeconomics prescribing pattern

Get full access to this article

View all access options for this article.

References

Canadian Cancer Society. Canadian Cancer Statistics 2008. Toronto, Ontario: National Cancer Institute of Canada, 2008.

Loblaw DA , Virgo KS , Nam R. , Somerfield MR , Ben-Josef E. , Mendelson DS et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25(12): 1596-605.

Geller J. , Albert J. , Loza D. , Geller S. , Stoeltzing W. , de la Vega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978; 46(3): 440-44.

Labrie F. , Dupont A. , Belanger A. Complete androgen blockade for the treatment of prostate cancer. In: DeVita Jr VT , Hellman S , Rosenberg SA. eds. Important advances in oncology. Philadelphia: JB Lippincott, 1985, 193-200.

Loblaw DA , Mendelson DS , Talcott JA , Virgo KS , Somerfield MR et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22(14): 2927-41.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM: Prostate cancer (V.2.2007). Available at: www.nccn.org (accessed May 4, 2007).

Schmitt B. , Wilt TJ , Schellhammer PF , DeMasi V. , Sartor O. , Crawford ED Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57(4): 727-32.

Samson DJ , Seidenfeld J. , Schmitt B. , Hasselblad V. , Albertsen PC , Bennett CL Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95(2): 361-76.

Eisenberger ME , Blumenstein BA , Crawford ED , Miller G. , McLeod DG , Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036-42.

10.

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355(9214): 1491-98.

11.

Akaza H. , Yamaguchi A. , Matsuda T. , Igawa M. , Kumon H. , Soeda A. et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34(1): 20-28.

12.

Usami M. , Akaza H. , Arai Y. , Hirano Y. , Kagawa S. , Kanetake H. et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 2007 ; 10(2): 194-201.

13.

Klotz L. , Schellhammer P. , Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93(9): 1177-82.

14.

Bondy SJ , Iscoe NA , Rothwell DM , Gort EH , Fleshner NE , Paszat LF et al. Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care 2001; 39(4): 384-96.

15.

Meng MV , Elkin EP , Latini DM , Duchane J. , Carroll PR Treatment of patients with high risk localized prostate cancer: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol 2005; 173(5): 1557-61.

16.

Jemal A. , Siegel R. , Ward E. , Hao Y. , Xu J. , Murray T. et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.

17.

BC Cancer Agency. Number of prevalent cancers by cancer type and year. Available at: http://www.bccancer.bc.ca/HPI/CancerStatistics/FF/Prev.htm#num2005-2020. (accessed June 1, 2007).

18.

Bubley GJ , Carducci M. , Dahut W. , Dawson N. , Daliani D. , Eisenberger M. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group [published erratum appears in J Clin Oncol 2000 Jul;18(13):2644] . J Clin Oncol 1999; 17(11): 3461-67.

19.

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-69.

20.

Bolla M. , Gonzalez D. , Warde P. , Dubois JB , Mirimanoff RO , Storme G. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.

21.

Pilepich MV , Caplan R. , Byhardt RW , Lawton CA , Gallagher MJ , Mesic JB et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of radiation therapy oncology group protocol 85-31. J Clin Oncol 1997; 15(3): 1013-21.

22.

Bolla M. , Collette L. , Blank L. , Lawton CA , Gallagher MJ , Mesic JB et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-08.

23.

Pilepich MV , Winter K. , John MJ , Mesic JB , Sause W. , Rubin P. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50(5): 1243-52.

24.

Pilepich MV , Winter K. , Lawton CA , Krisch RE , Wolkov HB , Movsas B. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 . Int J Radiat Oncol Biol Phys 2005; 61(5): 1285-90.

25.

Bayoumi AM , Brown AD , Garber AM Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92(21): 1731-39.